Gianni Belcaro

Gianni Belcaro

Auto-generated profile, based on publicly available information

Gianni Belcaro

IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy -

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2013 in Phytotherapy Research
Verified
Journal Article
Open access
PDF file
GBGianni Belcaro
Gianni Belcaro
MHMorio Hosoi
Morio Hosoi
LPLuciano Pellegrini
Luciano Pellegrini
Giovanni AppendinoGiovanni Appendino
Giovanni Appendino
EIEdmondo Ippolito
Edmondo Ippolito
STStefano Togni
Stefano Togni
A proprietary lecithin delivery system of curcumin (Meriva) was evaluated in a controlled study to assess its efficacy in alleviating the side effects of cancer chemo‐ and radiotherapy in 160 patients undergoing these treatments. In both cases, a semi‐quantitative evaluation of the side effects was carried out using a visual analogue scale, assessing also the plasma free radical status in all patients. Results showed that lecithinized curcumin might alleviate the burden of side effects associated to chemo‐ and radiotherapy, suggesting that the anecdotal use of various preparations of curcumin as a supportive agent for cancer treatment is well worth a systematic investigation in larger scale clinical trials. The capacity of curcumin to upregulate anti‐oxidative responses and downregulate inflammatory pathways could explain its beneficial effect in tempering the prolonged and systemic oxidative and inflammatory effects of cancer treatment, and the beneficial effects observed in the plasma oxidative status in all patients of the treatment group support this view. © 2013 The Authors. Phytotherapy Research published by John Wiley & Sons, Ltd.

2 August 2013 in Reproductive Biology and Endocrinology
Verified
Journal Article
Open access
PDF file
UCUmberto Cornelli
Umberto Cornelli
GBGianni Belcaro
Gianni Belcaro
MCMaria Rosaria Cesarone
Maria Rosaria Cesarone
AFAnnarosa Finco
Annarosa Finco
Background: Few data concerning the oxidative stress (OS) in plasma during the entire menstrual cycle of eumenorrheic women are available. Methods: OS was assessed in 20 healthy volunteers during the phase of the menstrual cycle by determining the plasmatic hydroperoxides levels (d-ROMs test). The assessment was performed every three days, starting from the first day (t1) up the end of the menstrual phase (t27). Concomitantly, the estrogen (E2) and progestin (P4) levels were determined at the same time intervals. Results: From a base value (t1) of 284 +/− 38.0 CARR.U., which is essentially within the normal range (300 CARR.U. Analysis of the E2 levels showed that the maximum OS values were noticed near the estrogen peak, while remaining above the base levels, and then decreased during the progestin phase until returning to normal at the end of the menstrual cycle. Conclusions: It may concludes that the healthy women go into OS for 2/3 of the menstrual cycle.

14 November 2013 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
GBGianni Belcaro
Gianni Belcaro
ALAndrea Ledda
Andrea Ledda
SHShu Hu
Shu Hu
MCMaria Rosa Cesarone
Maria Rosa Cesarone
BFBeatrice Feragalli
Beatrice Feragalli
MDMark Dugall
Mark Dugall
The beneficial effects of Greenselect Phytosome, a proprietary lecithin formulation of a caffeine-free green tea catechin extract, were evaluated in a controlled registry study on 50 asymptomatic subjects borderline for metabolic syndrome factors and with increased plasma oxidative stress. After 24 weeks of intervention, improvement in weight, blood lipid profile, and blood pressure positioned 68% of subjects in the treatment arm out of the metabolic syndrome profile, while 80% of the subjects in the control group still remained in their initial borderline disease signature. Compared to the control (lifestyle and dietary changes alone), Greenselect Phytosome was especially effective for weight/waist changes. These results highlight the relevance of addressing multiple factors involved in the development of metabolic syndrome with a pleiotropic agent capable of improving the beneficial effects of lifestyle and dietary changes and foster the attainment of a globally improved health profile.

1 January 2020 in Minerva Medica
Verified
Journal Article
Closed access
MCMaria R. Cesarone
Maria R. Cesarone
GBGianni Belcaro
Gianni Belcaro
SHShu Hu
Shu Hu
MDMark Dugall
Mark Dugall
MHMorio Hosoi
Morio Hosoi
RCRoberto Cotellese
Roberto Cotellese
BACKGROUND: In association with standard management, natural pharmaceutical standard (PS) supplements may play an important role in managing and preventing mild-to-moderate symptoms of asthma, a significant health issue that impacts patients and the healthcare system. Quercetin is a natural flavonoid with important biological properties (anti-inflammatory, antihistamine and anti-oxidative actions). METHODS: In this pilot registry, we evaluated the effects of quercetin formulated with the Phytosome (R) delivery system (Quercefit (TM), QFit)+standard management (SM) in otherwise healthy subjects with mild-moderate asthmatic attacks and rhinitis. Subjects used either QFit 1 or 2 tabs/day in association with SM or SM only (control group). After 30 days of management, we evaluated the presence of the main signs/symptoms of asthma according to the GINA classification system also considering the need of rescue medication, nasal drops, the use of inhalers, the rhinitis score and oxidative stress. RESULTS: QFit+SM showed superior results compared with SM alone in controlling, preventing and reducing daily and night symptoms, in maintaining higher peak expiratory flow (PEF) and in decreasing PEF variability. The supplementary use of QFit improved additional measures of asthma management, decreasing the use of inhalers, nasal drops, rescue medications and improving the rhinitis score. QFit produced a significantly more evident reduction in oxidative stress compared with SM; Qfit showed a very good safety profile. CONCLUSIONS: This preliminary supplement, concept registry shows a potential protective and preventive effect of quercetin on attacks frequency and in controlling the most common signs/symptoms of asthma in the milder cases of the disease.

19 September 2013 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
GBGianni Belcaro
Gianni Belcaro
ALAndrea Ledda
Andrea Ledda
SHShu Hu
Shu Hu
MCMaria Rosa Cesarone
Maria Rosa Cesarone
BFBeatrice Feragalli
Beatrice Feragalli
MDMark Dugall
Mark Dugall
The efficacy of a standardized grape seed procyanidins extract (GSPE, Enovita) to decrease blood pressure when associated with nondrug intervention (diet and lifestyle modifications) was investigated in a controlled registry study involving 119 healthy, pre- and mildly hypertensive subjects. Two dosages of Enovita were evaluated (150 and 300 mg/die), using blood pressure and heart rate as the primary endpoints and complementing these observations with a laser Doppler flowmetry (LDF) investigation of the microcirculation state and an evaluation of the plasma oxidative status. After four months of treatment, a statistically significant higher, and dose-dependent, improvement in all endpoints was observed in the treatment groups compared to that of the control, with blood pressure normalizing in 93% of the higher dosage (300 mg) treatment group. Taken together, these observations suggest that GSPEs have beneficial cardiovascular effects that complement current intervention strategies in the hypertension area. The effect on blood pressure adds to the beneficial effects of GSPEs on the cardiovascular disease (CVD) phenotype associated with the oxidation of membrane lipids (endothelial dysfunction, formation of oxidized LDL, and activation of phagocytic cells).

1 May 2006 in Angiology
Verified
Journal Article
Closed access
MVMaria Giulia Vinciguerra
Maria Giulia Vinciguerra
GBG. Belcaro
G. Belcaro
MCM. R. Cesarone
M. R. Cesarone
PRP. Rohdewald
P. Rohdewald
Stefano StuardStefano Stuard
Stefano Stuard
FFF. Fano
F. Fano
The aim of this study was to assess the preventive action of Pycnogenol® (Horphag Research Ltd, UK) on cramps and muscular pain in different groups of subjects and patients. The study included a 5-week observation period (4 weeks treatment and one follow-up week after the suspension of treatment) to evaluate the efficacy of Pycnogenol after its withdrawal. Four 50 mg capsules (total dose 200 mg/day) were prescribed with suggestion to drink at least 1.5 liters of water every day. In the first part of the study 66 healthy subjects completed a 5-week follow-up period. The difference between number of cramps attacks recorded within the 2 weeks before inclusion and the number of episodes during the fourth (p<0.05) and fifth (p<0.05) week were statistically significant. In normal subjects the average number of episodes was reduced from 4.8 (1.2) events per week to 1.3 (1.1) at 4 weeks (p<0.05). In venous patients the decrease in events was from 6.3 (1.1) to 2.6 (0.4) per week (p<0.05). In athletes the number of episodes decreased from 8.6 (2) to 2.4 (0.5) (p<0.05). The decrease was still present at 5 weeks in the 3 groups, to levels significantly lower than inclusion values (p<0.05). In the second part of the study, patients with intermittent claudication and diabetic microangiopathy were evaluated and treated (4 weeks). The groups treated with Pycnogenol and the control, placebo groups were comparable. There was a significant decrease in the number of cramps episodes (p<0.05) and in the score concerning muscular pain (p<0.05) in claudicants and diabetics. No significant effects were observed in the placebo groups. In conclusion, cramps and muscular pain, common in these 2 types of patients, were decreased by the use of Pycnogenol. Globally, these results suggest that the use of Pycnogenol prevents cramps, muscular pain at rest, and pain after/during exercise in normals, in athletes prone to cramps, in patients with venous disease, in claudicants, and in diabetics with microangiopathy. The difference is statistically significant considering objective observations (cramps episodes) and evaluating more subjective aspects (score). This indicates that Pycnogenol is effective in reducing pain and cramps during retraining and rehabilitation increasing its efficiency. In starting any physical rehabilitation program, particularly in vascular subjects, the limitation in mobility associated with muscular pain and with cramps tends to be relevant, and controlling these symptoms is useful to speed up the retraining process.